Korea to shorten screening period of phase 1 study

The Korea Food and Drug Administration says it will simplify the screening procedures of local phase 1 clinical trials here as part of efforts to make this country attractive for multinational pharmaceutical companies.

To this end, the drug agency said that beginning January 2011, it will shorten the screening period of clinical 1 study from the current 30 days to 14 days, provided that an a...